+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Global Neurovascular Devices Market Set To Grow To $3.3bn By 2022

03 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Neurovascular Devices Market Forecast to 2027 : Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, Neurothrombectomy Devices
The neurovascular devices market is segmented into Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, and Neurothrombectomy Devices. The market includes products such as clot retrieval devices, microcatheters, guidewires, stent retrievers, aspiration systems, etc.

The lead analyst of the report commented “The neurovascular devices market is driven by aging population, high incidence of obesity, increasing demand for minimally invasive procedures, and growing awareness of neurovascular diseases. In addition, technological advancements to develop new devices will further drive the market growth. The weaknesses of the market include high cost of devices and disadvantages of neurovascular devices.

However, increasing healthcare expenditures to provide better facilities and automated products showcase growing opportunities for the market growth. High cost of R&D activities and alternative medication therapies pose a major threat to the neurovascular devices market.”

Leading companies featured in the report include Stryker Corporation, Medtronic
Johnson & Johnson, Terumo, Penumbra.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Antibiotics Market Report 2023-2033

The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Human Microbiome Market Report 2023-2033

The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

30 January 2023

Read